BR112012008185A2 - composições que compreendem adjuvante, macrolídeo e antígeno proteináceo, e métodos para uso dessas composições - Google Patents

composições que compreendem adjuvante, macrolídeo e antígeno proteináceo, e métodos para uso dessas composições

Info

Publication number
BR112012008185A2
BR112012008185A2 BR112012008185A BR112012008185A BR112012008185A2 BR 112012008185 A2 BR112012008185 A2 BR 112012008185A2 BR 112012008185 A BR112012008185 A BR 112012008185A BR 112012008185 A BR112012008185 A BR 112012008185A BR 112012008185 A2 BR112012008185 A2 BR 112012008185A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
adjuvant
macrolide
proteinaceous antigen
Prior art date
Application number
BR112012008185A
Other languages
English (en)
Inventor
Nahla Fattohi
Terry Kaleung Ng
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of BR112012008185A2 publication Critical patent/BR112012008185A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

composições que compreendem adjuvante, macrolídeo e antígeno proteináceo, e métodos para uso dessas composições. a invenção refere-se a composições que compreendem um adjuvante óleo, uma lactona macrocíclica eficaz para a prevenção ou controle de infecção parasística em um animal de sangue quente e uma quantidade imunizante de pelo menos um polipeptídeo imunogênico, e a métodos de uso dessas composições.
BR112012008185A 2009-10-07 2010-09-29 composições que compreendem adjuvante, macrolídeo e antígeno proteináceo, e métodos para uso dessas composições BR112012008185A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24945409P 2009-10-07 2009-10-07
PCT/US2010/050630 WO2011043962A2 (en) 2009-10-07 2010-09-29 Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112012008185A2 true BR112012008185A2 (pt) 2016-08-16

Family

ID=43707921

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008185A BR112012008185A2 (pt) 2009-10-07 2010-09-29 composições que compreendem adjuvante, macrolídeo e antígeno proteináceo, e métodos para uso dessas composições

Country Status (9)

Country Link
US (1) US20110091559A1 (pt)
EP (1) EP2485725A2 (pt)
AR (1) AR078539A1 (pt)
AU (1) AU2010303741A1 (pt)
BR (1) BR112012008185A2 (pt)
MX (1) MX2012004133A (pt)
TW (1) TW201127398A (pt)
UY (1) UY32930A (pt)
WO (1) WO2011043962A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6692294B2 (ja) * 2013-07-31 2020-05-13 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 腫瘍関連糖鎖抗原を標的として癌を治療及び予防するための組成物及び方法
US10653766B2 (en) 2014-03-12 2020-05-19 Bavarian Nordic A/S Use of oil and water emulsions for increasing B cell responses with modified Vaccinia Ankara virus
GB201714057D0 (en) * 2017-09-01 2017-10-18 Univ College Dublin Nat Univ Of Ireland Dublin A fasciola hepatica antigen and vaccine
CN110898216B (zh) * 2019-12-31 2021-12-03 中国农业科学院兰州兽医研究所 重组旋毛虫硫氧还蛋白过氧化物酶2在制备抗旋毛虫感染疫苗中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4389397A (en) 1980-08-04 1983-06-21 Merck & Co., Inc. Solubilization of ivermectin in water
US4853372A (en) 1983-12-22 1989-08-01 Merck & Co., Inc. Non-aqueous ivermectin formulation with improved antiparasitic activity
ES8800986A1 (es) 1985-07-27 1987-12-01 Pfizer Un procedimiento para la produccion de un nuevo derivado de avermectina
US4886828A (en) 1986-09-12 1989-12-12 American Cyanamid Company Δ22 -derivatives of LL-F28249 compounds
US5019589A (en) 1986-09-12 1991-05-28 American Cyanamid Company Δ23 -LL-F28249 compounds
GB8813150D0 (en) 1988-06-03 1988-07-06 American Cyanamid Co Chemical compounds
ES2052173T3 (es) * 1989-04-11 1994-07-01 Pfizer Composiciones inyectables que contienen 25-cyclohexil-avermectina b1.
NZ234802A (en) 1989-08-14 1992-11-25 Merck & Co Inc Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals
US5030650A (en) 1989-09-11 1991-07-09 American Cyanamid Company 13-halo-23-imino derivatives of LL-F28249 compounds and their use as endo- and ectoparasiticidal, insecticidal, acaricidal and nematocidal agents
US5055486A (en) 1989-12-22 1991-10-08 American Cyanamid Company 13-alkyl-23-imino derivative of LL-F28249 compounds and their use as endo- and ectoparasiticidal, insecticidal, acaricidal and nematocidal agents
ES2086022T3 (es) 1991-07-23 1996-06-16 American Cyanamid Co Composiciones estables para administracion parenteral y su uso.
EP0666919B1 (en) 1992-10-21 2003-05-14 John Pius Dalton Vaccine containing a thiol protease
AU5996294A (en) * 1993-02-05 1994-08-29 Daratech Pty Ltd Polypeptides obtainable from species of fasciola, and vaccines, methods of treatment and DNA sequences of the same
GB9312324D0 (en) 1993-06-15 1993-07-28 Pitman Moore Inc Vaccine
AU7349596A (en) 1995-05-17 1996-12-11 International Centre of Insect Physiology and Ecology, The Novel method of enhancing efficiency of anti-arthropod agents against blood-feeding ectoparasites
ATE214603T1 (de) 1995-06-30 2002-04-15 American Cyanamid Co Stabile makrolide und makrolide imptstoff- zusammensetzungen
AU713580B2 (en) * 1995-09-25 1999-12-02 Merial Ltd Anthelmintic macrocyclic lactone compositions
CA2259469A1 (en) * 1996-06-05 1997-12-11 Ashmont Holdings Limited Injectable compositions
GB9612214D0 (en) 1996-06-11 1996-08-14 Mallinckrodt Veterinary Inc Vaccine
EP2281572A1 (en) * 2001-07-27 2011-02-09 Wyeth LLC West Nile Vaccine
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
TW201010719A (en) * 2008-08-19 2010-03-16 Wyeth Corp Immunological composition

Also Published As

Publication number Publication date
WO2011043962A2 (en) 2011-04-14
TW201127398A (en) 2011-08-16
EP2485725A2 (en) 2012-08-15
AU2010303741A1 (en) 2012-04-19
AR078539A1 (es) 2011-11-16
WO2011043962A3 (en) 2011-06-03
MX2012004133A (es) 2012-05-08
UY32930A (es) 2011-05-31
US20110091559A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
EA200900350A1 (ru) Вакцина, содержащая адъювант в виде эмульсии "масло в воде"
EA201001479A1 (ru) Вакцина
BRPI1013780A2 (pt) composições para imunização contra staphylococcus aureus.
BR112012019098B8 (pt) anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica
BR112012027747A2 (pt) método e composição imunogênica para tratamento de neoplásia
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
CL2013001673A1 (es) Composicion acuosa que comprende aproximadamente 18% p/v de concentracion, donde al menos el 95% de las proteinas son igg; metodo mejorado para preparar dicha composición.
DK1954308T3 (da) Stabiliseringsmidler til frysetørrede vacciner
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
BR112015013700A2 (pt) composição, sequência nucleotídica, anticorpo sintético, e, uso da composição
BRPI0715396B8 (pt) método de produção de uma composição para vacina
BRPI0708344A8 (pt) Vetores adenovirais quiméricos e composição imunogênica
BRPI0621181A8 (pt) Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico
CL2011002639A1 (es) Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis.
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
BR112012014933A2 (pt) composições que compreendem compostos macrocíclicos lactona e spirodioxepinoindóis
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
BR112016015422A2 (pt) formulações de vacina de frasco único
BR112015008419A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina
BR112012008185A2 (pt) composições que compreendem adjuvante, macrolídeo e antígeno proteináceo, e métodos para uso dessas composições
EA201001478A1 (ru) Вакцина
AR059851A1 (es) Anticuerpos de la egfl7 y metodos de uso
BR112017012348A2 (pt) tensoativo de açúcar e uso do mesmo em composições agroquímicas
CL2008002320A1 (es) Método para identificar una proteína de streptococus uberis que sea capaz de producir una respuesta inmune en contra de a lo menos dos cepas de streptococcus uberis.
WO2008043000A3 (en) Ehrlicia canis diva (differentiate infected from vaccinated animals)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PAH W LLC (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B25D Requested change of name of applicant approved

Owner name: ZOETIS W LLC (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]